{"id":"ab001","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Pneumonitis"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"20-30%","effect":"Fatigue"}]},"_chembl":null,"_fixedAt":"2026-03-30T18:00:17.635399","_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, AB001 prevents the interaction between PD-1 and its ligands, leading to the activation of T cells and enhanced anti-tumor immune response.","oneSentence":"AB001 is a small molecule that targets the PD-1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:28:08.399Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer, PD-L1 positive"},{"name":"Metastatic melanoma"}]},"_fixedFields":["pubmed(19)"],"trialDetails":[{"nctId":"NCT07214961","phase":"PHASE1","title":"Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)","status":"RECRUITING","sponsor":"ARTBIO Inc.","startDate":"2025-11-03","conditions":"Prostate Cancer (CRPC), Metastatic Castrate Resistant Prostate Cancer (mCRPC)","enrollment":80},{"nctId":"NCT06126094","phase":"NA","title":"Benefits of Alcoholic Hangover Medicine","status":"UNKNOWN","sponsor":"The Gut Microbiome Center (Centar za crijevni mikrobiom)","startDate":"2023-10-31","conditions":"Gastrointestinal Microbiome","enrollment":2},{"nctId":"NCT03997734","phase":"PHASE1","title":"Tolerability, Safety and Pharmacokinetics of a Topical AB001 Patch in Healthy Subjects","status":"COMPLETED","sponsor":"Frontier Biotechnologies Inc.","startDate":"2019-06-24","conditions":"Chronic Low Back Pain","enrollment":34},{"nctId":"NCT02436824","phase":"PHASE2","title":"A Study of a Topical Patch (AB001) in Patients With Chronic Low Back Pain","status":"COMPLETED","sponsor":"Frontier Biotechnologies Inc.","startDate":"2015-04","conditions":"Chronic Low Back Pain","enrollment":146}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19,"recentPublications":[{"date":"2025 Nov 29","pmid":"41318731","title":"Cytotoxicity and cell cycle changes in prostate cancer cells with differing PSMA expression and p53 status after treatment with PSMA-targeting radioligand [(212)Pb]Pb-AB001.","journal":"Scientific reports"},{"date":"2025 Dec 3","pmid":"41043994","title":"Optimizing [(212)Pb]Pb-AB001 Radiopharmaceutical Therapy Schedules in PSMA-Positive Subcutaneous Prostate Cancer Xenografts.","journal":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine"},{"date":"2025 Jul 22","pmid":"40694184","title":"Combination of PSMA targeting alpha-emitting radioligand [(212)Pb]Pb-AB001 with BET bromodomain inhibitors in in vitro prostate cancer models.","journal":"Medical oncology (Northwood, London, England)"},{"date":"2025 Nov","pmid":"40397137","title":"Therapeutic evaluation of [(212)Pb]Pb-AB001 and [(177)Lu]Lu-PSMA-617 in a mouse model of disseminated prostate cancer.","journal":"European journal of nuclear medicine and molecular imaging"},{"date":"2025 May 1","pmid":"40081958","title":"First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen-Targeted (212)Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer.","journal":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["topical patch","AB001"],"phase":"phase_2","status":"active","brandName":"AB001","genericName":"AB001","companyName":"Frontier Biotechnologies Inc.","companyId":"frontier-biotechnologies-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AB001 is a small molecule that targets the PD-1 receptor. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic melanoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}